Physician profile
Larry M Borowsky
NPI 1174506729
$8,626.53
in general payments reported to CMS, 2019-2025
31 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $1,412 · 2021: $1,674 · 2022: $1,538 · 2023: $1,022 · 2024: $1,127 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $14.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.24 |
| Education | $14.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,787.42 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $1,747.92 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Qol Medical, LLC | $1,003.37 | 2019-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $727.86 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $508.45 | 2019-2024 | |
| Celgene Corporation | $321.70 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $278.60 | 2020-2023 | |
| Janssen Biotech, INC. | $264.17 | 2019-2023 | Stelara |
| Redhill Biopharma INC. | $240.47 | 2020-2022 | |
| Braintree Laboratories, INC. | $223.62 | 2020-2024 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $189.96 | 2019-2023 | Dificid |
| Pfizer INC. | $180.98 | 2020-2025 | |
| Conmed Corporation | $164.86 | 2025 | Conmed Generators, Conmed Biliary, Conmed Dilation |
| Ironwood Pharmaceuticals, INC | $133.70 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $130.05 | 2024-2025 | Zenpep |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $128.31 | 2019-2020 | |
| Vivus LLC | $73.90 | 2019-2022 | |
| Ardelyx, INC. | $65.73 | 2023-2024 | Ibsrela |
| Allergan, INC. | $60.40 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $60.19 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $55.20 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $54.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Alfasigma USA, INC. | $43.77 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $38.80 | 2024 | Bylvay |
| Genzyme Corporation | $35.12 | 2023-2024 | |
| Evoke Pharma, INC. | $26.14 | 2020-2021 | |
| Meridian Bioscience INC. | $21.32 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $17.68 | 2024 | Dupixent |
| Celltrion USA INC. | $14.80 | 2024 | Zymfentra |
| Shionogi INC | $14.49 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Borowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.